The European Commission Has Approved ViiV Healthcare's Apretude (Cabotegravir Long-acting Injectable And Tablets) For HIV Prevention In High-risk Adults And Adolescents
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved ViiV Healthcare's Apretude for HIV prevention in high-risk adults and adolescents. ViiV Healthcare is owned by GSK, Pfizer, and Shionogi.
September 19, 2023 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK, as a shareholder of ViiV Healthcare, stands to benefit from the European Commission's approval of Apretude.
As a major shareholder in ViiV Healthcare, GSK is likely to see a positive impact on its stock price following the approval of Apretude by the European Commission. This approval could lead to increased revenues for ViiV Healthcare, and by extension, GSK.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, a shareholder of ViiV Healthcare, could see a positive impact following the European Commission's approval of Apretude.
Pfizer, as a shareholder in ViiV Healthcare, is likely to benefit from the approval of Apretude by the European Commission. This approval could lead to increased revenues for ViiV Healthcare, and by extension, Pfizer.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80